Take Five: Coronavirus vaccine race is on
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Novavax (NVAX) Begins Phase 1/2 Clinical Trial of COVID-19 Vaccine
May 26, 2020 5:53 AM EDTNovavax, Inc. (NASDAQ: NVAX) today announced enrollment of the first participants in a Phase 1/2 clinical trial of its coronavirus vaccine candidate, NVXCoV2373, a stable, prefusion protein made using its proprietary nanoparticle technology. NVXCoV2373 includes Novavax proprietary MatrixM adjuvant to enhance immune responses and stimulate high levels of neutralizing antibodies. Preliminary immunogenicity and safety results from the Phase 1 portion of the trial are expected in July 2020.
Administering our vaccine in the first participants of this clinical trial is a significant achievement, bringing us one step closer toward addressing the... More
